Tau Scaffolding Interactions

Tau Scaffolding Interactions enters the Adult Cognitive Disease corpus through the work of Varghese John (submission 78), and is indexed here as one of the concepts that submission puts to work.

The argument it belongs to

Varghese John's submission is summarised in this corpus as:

Apolipoprotein E4 (ApoE4), the major genetic risk factor for sporadic late-onset Alzheimer's disease, exerts a broad panoply of pro-AD effects rather than acting through a single pathway. ApoE4 shifts APP processing toward amyloidogenic cleavage (raising BACE1, lowering ADAM10/sAPPalpha), represses the longevity deacetylase Sirtuin 1 (SirT1), and drives mitochondrial dysfunction, lysosomal leakage, and tau phosphorylation. The proposal applies a systems-pharmacology drug-discovery approach to develop first-in-class, brain-permeable small molecules that target these ApoE4 mechanisms for multi-modal AD therapy.

Where it sits

The submission scores against the framework's convergence nodes as: endosomal nexus 9 · ApoE4 hub 9 · transcriptional / epigenetic 8 · cytoskeletal collapse 2 · compensatory paradigm 2 · neuroimmune interface 1.

Its declared subject matter: apoe4, systems-pharmacology, sirtuin-1, app-processing, bace1, adam10, lysosomal-dysfunction, multi-modal-therapy.

Named by the same submission

7 other concepts enter the corpus through the same paper, so they cover adjacent ground: Autophagy · Endolysosomal Dysfunction · Epigenetic Repression · Selective Tau Disruption · Systems Biology · Tau Propagation · Vesicular Trafficking.

Assembled from the corpus rather than written: the summary is quoted from the submission that named it; the node scores are read from its dossier. It has not yet been expanded into an article.